Listed by the USPTO as SMITH, EMILIE ALINE
Tech Center 1600 • Art Units: 1637 1671 1686
This examiner grants 49% of resolved cases
SMITH, EMILIE ALINE works in Tech Center 1600 and Art Unit 1637. Her record includes 77 resolved cases, with a 49.4% allowance rate and a 35.4% interview lift. The median time to allowance is 1589 days.
Her listed companies are NEC Laboratories America Inc., Genome International Corporation, and NEC Corporation. Her listed firms are FOLEY & LARDNER LLP, GOODWIN PROCTER LLP, and Knobbe, Martens, Olson & Bear, LLP. The limited case volume calls for care in applying the figures, but the interview lift identifies examiner interviews as a potentially useful prosecution tool.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17192530 | METHOD FOR GENERATING COMPOUND STRUCTURE, PROGRAM FOR GENERATING COMPOUND STRUCTURE, AND DEVICE FOR GENERATING COMPOUND STRUCTURE | Final Rejection | FUJIFILM Corporation |
| 17788304 | METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN | Final Rejection | NEC Corporation |
| 18323443 | COMPUTER-READABLE RECORDING MEDIUM STORING INFORMATION PROCESSING PROGRAM, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING DEVICE | Non-Final OA | Fujitsu Limited |
| 17914279 | ATHLETIC PERFORMANCE ESTIMATION APPARATUS, ATHLETIC PERFORMANCE ESTIMATION METHOD, AND PROGRAM | Final Rejection | NTT, Inc. |
| 18414645 | T-CELL RECEPTOR OPTIMIZATION WITH REINFORCEMENT LEARNING AND MUTATION POLICIES FOR PRECISION IMMUNOTHERAPY | Non-Final OA | NEC Laboratories America, Inc. |
| 18151686 | T-CELL RECEPTOR OPTIMIZATION WITH REINFORCEMENT LEARNING AND MUTATION POLICIES FOR PRECISION IMMUNOTHERAPY | Non-Final OA | NEC Laboratories America, Inc. |
| 18195744 | METHODS FOR TRAINING MOLECULAR BINDING MODELS, METHODS FOR SCREENING MOLECULES, APPARATUSES, COMPUTER DEVICES AND STORAGE MEDIA | Non-Final OA | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED |
| 17755713 | Systems and Methods for Deconvoluting Tumor Ecosystems for Personalized Cancer Therapy | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18306737 | Transcriptome Analysis For Treating Inflammation | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17756068 | SYSTEMS AND METHODS FOR CONTAMINATION DETECTION IN NEXT GENERATION SEQUENCING SAMPLES | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 17920012 | COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER | Non-Final OA | Myriad Genetics, Inc. |
| 17833394 | METHODS AND SYSTEMS FOR IDENTIFYING RECOMBINANT VARIANTS | Non-Final OA | Illumina, Inc. |
| 17931616 | HYBRID QUANTUM-CLASSICAL COMPUTING SIMULATION OF CHEMICAL SYSTEMS | Non-Final OA | Quantinuum LLC |
| 17766031 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | Non-Final OA | CLARET BIOSCIENCE, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.4% of resolved applications examined by Emilie Aline Smith were allowed (77 resolved cases), compared with 45.4% across Art Unit 1637 over the last five years.
This examiner's interview lift is +35.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Emilie Aline Smith took 1,589 days on average from filing to allowance.
Emilie Aline Smith examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
